Fundraising Fox
/Companies
Sign in

Alentis Therapeutics

Basel, CH · Founded 2019 · 70 employees on LinkedIn · 12 known investors

Find your way into Alentis Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

196 people can intro you to Thomas

Ask Cristina Ghenoiu to introduce you to Thomas Baumert

You →Cristina · together at Universitätsklinikum Freiburg →Thomas

44 people can intro you to Luigi

Ask Jamie Chen to introduce you to Luigi Manenti

You →Jamie · together at HiFiBiO Therapeutics →Luigi

Sign up to find every way you can get introduced to Alentis Therapeutics

  • Your email: who you already know at Alentis Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alentis Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.

AI & Machine LearningBiotechHealthtechMedical Devices

Founders & leadership

Alentis Therapeutics was founded in 2019 by Thomas Baumert.

TBThomas Baumert
Thomas BaumertFounderThomas Baumert holds an MD from the University of Heidelberg and completed training in internal medicine and gastroenterology at Ludwig Maximilians University Munich and the University Hospital Freiburg. He served as a fellow at Harvard Medical School and the NIH Liver Diseases Branch, became an associate professor in Freiburg, and is currently a professor of medicine at the University of Strasbourg and director of the Inserm Institute for Translational Medicine, with research focused on fibrosis and cancer therapies; he founded Alentis Therapeutics.
MPMark Pruzanski
Mark PruzanskiChief Executive OfficerChief Executive Officer at Alentis
LMLuigi Manenti
Luigi ManentiChief Medical OfficerLuigi Manenti is Chief Medical Officer at Alentis Therapeutics, a clinical-stage biotech company developing therapies for liver disease and cancer. He holds an MD in Medicine from Università di Pavia and has held senior leadership roles in clinical development and oncology at Roche, Novartis, and HiFiBiO Therapeutics, where he worked on antibody discovery and immuno-oncology programs.
JFJon Freve
Jon FreveChief Financial OfficerChief Financial Officer at Alentis
BYBryan Yoon
Bryan YoonGeneral Counsel and Chief Administrative OfficerExecutive Officer at Terns Pharmaceuticals
AVAditya Venugopal
Aditya VenugopalChief Business OfficerChief Business Officer at Alentis
ATAlberto Toso
Alberto TosoChief Scientific OfficerChief Scientific Officer at Alentis
RMRoberta Marchione
Roberta MarchioneChief Technology OfficerChief Technology Officer at Alentis

Investors · 12

BioMedPartners✓ confirmed by Alentis TherapeuticsBasel · $648K – $6.5M

How we know: BioMedPartners's portfolio page · the company's own site · the VCSheet dataset · Not right? Tell us

Frazier Life Sciences✓ confirmed by Alentis TherapeuticsPalo Alto

How we know: the company's own site · Frazier Life Sciences's portfolio page · Not right? Tell us

Jeito Capital✓ confirmed by Alentis TherapeuticsParis

How we know: Jeito Capital's portfolio page · the company's own site · Not right? Tell us

Longitude Capital✓ confirmed by Alentis TherapeuticsMenlo Park · $10M – $30M

How we know: the company's own site · Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us

Novo Holdings✓ confirmed by Alentis TherapeuticsCopenhagen · $1.1M – $54M

How we know: Novo Holdings's portfolio page · the company's own site · Not right? Tell us

OrbiMed✓ confirmed by Alentis TherapeuticsNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the company's own site · funding news · the VCSheet dataset · Not right? Tell us

RA Capital✓ confirmed by Alentis TherapeuticsBoston

How we know: RA Capital's portfolio page · the company's own site · Not right? Tell us

Bpifrance✓ confirmed by Alentis TherapeuticsParis, Ile-De-France · $270K

How we know: the company's own site · Not right? Tell us

Catalio Capital Management✓ confirmed by Alentis TherapeuticsNew York

How we know: the company's own site · Not right? Tell us

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

Pureos Bioventureslisted by Pureos BioventuresPfäffikon

How we know: Pureos Bioventures's portfolio page · Not right? Tell us

In the news

Alentis Therapeutics Raises $181.4M in Series D Fundingfinsmes.com · Nov 2024Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors - Alentis Therapeuticsalentis.ch · Nov 2024Alentis Therapeutics Raises US$105M in Series C Fundingfinsmes.com · Apr 2023Investors - Alentis Therapeuticsalentis.ch · Jul 2020News - Alentis Therapeuticsalentis.ch · Apr 2019

Frequently asked questions

What does Alentis Therapeutics do?
Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.
Who founded Alentis Therapeutics?
Alentis Therapeutics was founded by Thomas Baumert in 2019.
Who are Alentis Therapeutics's investors?
Alentis Therapeutics's investors include Avego BioScience Capital, BioMedPartners, Frazier Life Sciences, Jeito Capital, Longitude Capital, Novo Holdings, OrbiMed, RA Capital and 4 more.
Where is Alentis Therapeutics headquartered?
Alentis Therapeutics is headquartered in Basel, CH.